Clinical Trial Update: Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 expanded Lung-MAP trial evaluating a MET-targeted therapy for advanced non-small cell lung cancer with MET gene amplification; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MET-targeted therapy (investigational)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Lung Non-Small Cell Carcinoma | Phase 2 | Status: RECRUITING